Predicting Immunotherapy Response in Head and Neck Cancer
Only a subset of patients benefit from checkpoint blockade therapy, yet existing biomarkers frequently fail to predict response before treatment begins.
92%
predictive accuracy
50+
responder-associated spatial phenotypes
90%
reduction in projected analysis costs
APPROACH
Stratica partnered with investigators at a leading academic cancer center to analyze a Phase II immunotherapy trial using spatial proteomics, digital pathology, and StraticaOS-enabled virtual tissue modeling.
KEY OUTCOMES
50+ responder-associated spatial phenotypes
92% predictive accuracy
90% reduction in projected analysis costs
Weeks instead of months for analysis
Novel biomarker candidates identified
Companion diagnostic opportunities generated
IMPACT
Demonstrated how multicellular tissue programs outperform single-marker approaches for predicting therapeutic response.
APPLICATIONS
Drug Repurposing and Precision Stratification in Autoimmune Disease
Ready to build the next case study?
Stratica helps partners move from complex human biology to actionable therapeutic insight.